OBJECTIVES:
The purpose of this study was to evaluate supply cost differences and clinical outcomes with and without the intrauterine morcellator, and to determine predictors of its use for hysteroscopic polypectomy. MATERIALS AND METHODS: Hysteroscopic polypectomy cases performed at two hospitals in southwest Ohio between January 2013 and October 2017 were included. Patient and surgeon characteristics, surgical outcomes, and follow-up data were obtained from chart review. Categorical variables were analyzed using Chi-square while T-test or Wilcoxon Rank Sum were used for the continuous variables as appropriate. Logistic regression was used to model variables predicting morcellator use. RESULTS: The sample included 260 hysteroscopic polypectomies performed by 14 surgeons. Of these, 174 (67%) used the morcellator and 86 (33%) did not. The study variable most predictive of morcellator use was surgeon identity. Supply cost with morcellator use was significantly greater than for cases without morcellator use ($1451 vs. $188, p<0.001). Operating room times were similar between groups (60 vs. 58 minutes, p¼0.67). Pathologic specimen volumes were greater with the morcellator among premenopausal women (median 2.2 cm 3 vs. 1.6 cm 3 , p¼0.03), but no difference was identified among postmenopausal women (2.6 cm 3 vs. 1.9 cm 3 , p¼0.11). Rates of persistent or recurrent abnormal uterine bleeding (AUB) within one year following polypectomy were similar between groups (12% vs. 20%, p¼0.08), and rates of subsequent procedures for management of bleeding were also similar (4.3% vs. 8.8%, p¼0.17). CONCLUSION: A large cost differential exists between hysteroscopic polypectomy using the intrauterine morcellator versus mechanical tissue removal. While among premenopausal women more tissue was recovered, this was not true among postmenopausal women. Persistent or recurrent AUB was similar irrespective of technique. Surgeon identity was the most predictive factor of morcellator use. These findings suggest use of the intrauterine morcellator for polypectomy is low value and influencing surgeon behavior may help to increase cost-effectiveness with this procedure for this indication. 
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OBJECTIVES:
The objective of this study was to evaluate the incidence of and risk factors for early small bowel obstruction (SBO), occurring within the first month of surgery, after benign hysterectomy. MATERIALS AND METHODS: This was a retrospective cohort study using data from the American College of Surgeons National Surgical Quality Improvement Program database from 2014 to 2016. Current Procedural Terminology codes were used to identify patients undergoing hysterectomy for benign indications with or without concomitant colpopexy, lysis of adhesions (LOA), adnexectomy, or appendectomy. Patient demographics, clinical and surgical factors were obtained. Patients were then stratified into those with and without and SBO. Differences between groups were evaluated using Chi-squared and Fisher's exact tests for categorical variables, and the Student's t-test for continuous variables. Multivariable logistic regression was used to identify significant independent predictors of SBO. OBJECTIVES: To determine if cerebral small vessel ischemic disease (SVID) affects the rate of response to antimuscarinic medications for treating overactive bladder (OAB) symptoms.
MATERIALS AND METHODS:
This retrospective matched-cohort of patients treated for OAB with antimuscarinics between January 2010 and December of 2017. Patients were included if they had never been evaluated by a urogynecologist in the past with a chief complaint related to OAB were included and were treated with a maximum effective dose of an antimuscarinic for a minimum of 4 weeks and underwent head computed tomography (CT) within 12 months of starting therapy. All patients had to have explicit documentation of treatment adherence and whether there was a satisfactory therapeutic response. Patients with SVID were matched 1:1 by age and number of prior failed antimuscarinics to controls with normal head CTs. Exclusion criteria included incomplete documentation of adherence or therapeutic response, non-SVID CT abnormalities, OAB symptoms occurring within 6 months of pelvic surgery, genitourinary malignancy, evidence of urinary retention, and neurogenic bladder. The primary outcome was antimuscarinic treatment failure. Pairwise analysis between groups was performed using Wilcoxon Rank-Sum and Fisher's exact test where appropriate. Univariate logistic regression was performed and any variable that was associated with treatment failure and a p-value 0.2 was included in the multivariable regression analysis. RESULTS: A total of 68 cases were matched with 68 controls. Table 1 shows the demographic characteristics of the two groups and table 2 shows the clinical characteristics. There were no significant differences between the two groups except that patients with SVID were more likely to have undergone hysterectomy, 57.4% vs 41.2%, p¼0.04. Patients with SVID were more likely to fail antimuscarinic treatment compared to controls (60.7% vs 29.4%, p¼0.004). After adjusting for confounders, SVID was strongly associated with an increased probability of failure (aOR¼ 4.19, ). An active diagnosis of anxiety or depression (aOR ¼ 2.70, 95% CI: 1.15-6.33) and increasing number of daily urgency incontinence episodes (aOR ¼ 1.32 per episode, 95% CI: 1.08-1.61) were also associated with treatment failure. CONCLUSION: SVID is independently associated with anti-muscarinic treatment failure in women with overactive bladder symptoms.
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